Pharmacogenomics to Predict Tumor Therapy Response: A Focus on ATP-Binding Cassette Transporters and Cytochromes P450
Pharmacogenomics is an evolving tool of precision medicine. Recently, due to the introduction of next-generation sequencing and projects generating “Big Data”, a plethora of new genetic variants in pharmacogenes have been discovered. Cancer resistance is a major complication often preventing success...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-08-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/10/3/108 |
| _version_ | 1797555257652281344 |
|---|---|
| author | Viktor Hlaváč Petr Holý Pavel Souček |
| author_facet | Viktor Hlaváč Petr Holý Pavel Souček |
| author_sort | Viktor Hlaváč |
| collection | DOAJ |
| description | Pharmacogenomics is an evolving tool of precision medicine. Recently, due to the introduction of next-generation sequencing and projects generating “Big Data”, a plethora of new genetic variants in pharmacogenes have been discovered. Cancer resistance is a major complication often preventing successful anticancer treatments. Pharmacogenomics of both somatic mutations in tumor cells and germline variants may help optimize targeted treatments and improve the response to conventional oncological therapy. In addition, integrative approaches combining copy number variations and long noncoding RNA profiling with germline and somatic variations seem to be a promising approach as well. In pharmacology, expression and enzyme activity are traditionally the more studied aspects of ATP-binding cassette transporters and cytochromes P450. In this review, we briefly introduce the field of pharmacogenomics and the advancements driven by next-generation sequencing and outline the possible roles of genetic variation in the two large pharmacogene superfamilies. Although the evidence needs further substantiation, somatic and copy number variants as well as rare variants and common polymorphisms in these genes could all affect response to cancer therapy. Regulation by long noncoding RNAs has also been shown to play a role. However, in all these areas, more comprehensive studies on larger sets of patients are needed. |
| first_indexed | 2024-03-10T16:44:52Z |
| format | Article |
| id | doaj.art-62c835d2bebf4cc68a40fefec487559b |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-10T16:44:52Z |
| publishDate | 2020-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-62c835d2bebf4cc68a40fefec487559b2023-11-20T11:42:05ZengMDPI AGJournal of Personalized Medicine2075-44262020-08-0110310810.3390/jpm10030108Pharmacogenomics to Predict Tumor Therapy Response: A Focus on ATP-Binding Cassette Transporters and Cytochromes P450Viktor Hlaváč0Petr Holý1Pavel Souček2Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech RepublicToxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech RepublicToxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech RepublicPharmacogenomics is an evolving tool of precision medicine. Recently, due to the introduction of next-generation sequencing and projects generating “Big Data”, a plethora of new genetic variants in pharmacogenes have been discovered. Cancer resistance is a major complication often preventing successful anticancer treatments. Pharmacogenomics of both somatic mutations in tumor cells and germline variants may help optimize targeted treatments and improve the response to conventional oncological therapy. In addition, integrative approaches combining copy number variations and long noncoding RNA profiling with germline and somatic variations seem to be a promising approach as well. In pharmacology, expression and enzyme activity are traditionally the more studied aspects of ATP-binding cassette transporters and cytochromes P450. In this review, we briefly introduce the field of pharmacogenomics and the advancements driven by next-generation sequencing and outline the possible roles of genetic variation in the two large pharmacogene superfamilies. Although the evidence needs further substantiation, somatic and copy number variants as well as rare variants and common polymorphisms in these genes could all affect response to cancer therapy. Regulation by long noncoding RNAs has also been shown to play a role. However, in all these areas, more comprehensive studies on larger sets of patients are needed.https://www.mdpi.com/2075-4426/10/3/108cancer therapyresponsepharmacogenomicsATP-binding cassette transporterscytochromes P450omics |
| spellingShingle | Viktor Hlaváč Petr Holý Pavel Souček Pharmacogenomics to Predict Tumor Therapy Response: A Focus on ATP-Binding Cassette Transporters and Cytochromes P450 Journal of Personalized Medicine cancer therapy response pharmacogenomics ATP-binding cassette transporters cytochromes P450 omics |
| title | Pharmacogenomics to Predict Tumor Therapy Response: A Focus on ATP-Binding Cassette Transporters and Cytochromes P450 |
| title_full | Pharmacogenomics to Predict Tumor Therapy Response: A Focus on ATP-Binding Cassette Transporters and Cytochromes P450 |
| title_fullStr | Pharmacogenomics to Predict Tumor Therapy Response: A Focus on ATP-Binding Cassette Transporters and Cytochromes P450 |
| title_full_unstemmed | Pharmacogenomics to Predict Tumor Therapy Response: A Focus on ATP-Binding Cassette Transporters and Cytochromes P450 |
| title_short | Pharmacogenomics to Predict Tumor Therapy Response: A Focus on ATP-Binding Cassette Transporters and Cytochromes P450 |
| title_sort | pharmacogenomics to predict tumor therapy response a focus on atp binding cassette transporters and cytochromes p450 |
| topic | cancer therapy response pharmacogenomics ATP-binding cassette transporters cytochromes P450 omics |
| url | https://www.mdpi.com/2075-4426/10/3/108 |
| work_keys_str_mv | AT viktorhlavac pharmacogenomicstopredicttumortherapyresponseafocusonatpbindingcassettetransportersandcytochromesp450 AT petrholy pharmacogenomicstopredicttumortherapyresponseafocusonatpbindingcassettetransportersandcytochromesp450 AT pavelsoucek pharmacogenomicstopredicttumortherapyresponseafocusonatpbindingcassettetransportersandcytochromesp450 |